Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Pfizer Inc. for co-development and co-commercialization of multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.…
Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
Is Early B Cell Cancer Data Altering The Investment Case For Nurix Therapeutics (NRIX)?
Nurix Therapeutics (NASDAQ: NRIX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 317 employees.
The shares were at 12.85 USD on 20 November 2026, up 4.4% over 52 weeks. Its 52-week range is 12.01 USD to 28.23 USD: the price is 54.5% below the high and 7.0% above the low.
At a market capitalisation of 1.40B USD, it trades at 5.3 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 84% for NRIX.
Nurix Therapeutics reports return on equity of -49.1% and an operating margin of 41.3%.
It holds more cash than debt, a net cash position of 982.92M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 33.50 USD is 160.7% above the current price. The next earnings report is expected on 28 January 2027.